Apixaban; Betrixaban; Edoxaban; Rivaroxaban/NSAIDs Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
These medicines decrease your body's ability to make clots.
What might happen:
Using these medicines together may increase your risk of bleeding.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Let your doctor know right away if you have any unusual or unexpected bleeding such as bleeding from your gums, nosebleeds, unusual bruising, or dark stools.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Eliquis (apixaban) Australian prescribing information. Bristol-Myers Squibb Australia Pty. Ltd. July 21, 2011.
- 2.Eliquis (apixaban) Canadian prescribing information. Bristol-Myers Squibb-Pfizer March 12, 2019.
- 3.Eliquis (apixaban) UK summary of product characterstics. Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb House November 19, 2012.
- 4.Eliquis (apixaban) US prescribing information. Bristol-Myers Squibb Company June, 2019.
- 5.Savaysa (edoxaban) US prescribing information. Daiichi Sankyo, Inc September, 2016.
- 6.Xarelto (rivaroxaban) US prescribing information. Janssen Pharmaceuticals, Inc. August, 2019.
- 7.Bevyxxa (betrixaban) US prescribing information. Portola Pharmaceuticals, Inc. July, 2019.
- 8.Mendell J, Lee F, Chen S, Worland V, Shi M, Samama MM. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. J Cardiovasc Pharmacol 2013 Aug;62(2):212-21.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.